Procaps Group Depreciation And Amortization Over Time
| PROCW Stock | USD 0.03 0.0005 1.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Procaps Group Performance and Procaps Group Correlation. Procaps |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Revenue Per Share 4.097 | Quarterly Revenue Growth 0.073 | Return On Assets 0.0628 | Return On Equity 0.3737 |
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Depreciation And Amortization Analysis
Compare Procaps Group SA and related stocks such as Evoke Pharma, Dynavax Technologies, and Amphastar P Depreciation And Amortization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVOK | 10.7 K | 10.7 K | 1.7 K | 7.2 K | 10.2 K | 303.2 K | (597.6 K) | 1 M | 463.8 K | 7.2 M | 13 M | 8.2 M | 7.8 M | 138.6 K | 131.7 K |
| DVAX | (2.1 M) | 1.6 M | 1.2 M | 1.3 M | 1.4 M | 1.4 M | 2.3 M | 1.2 M | 14.5 M | 6.7 M | 9.3 M | 7 M | 6.7 M | 7.3 M | 3.7 M |
| AMPH | 11.2 M | 11.2 M | 11.5 M | 13.1 M | 14.4 M | 13.3 M | 14.6 M | 52.5 K | 16.5 M | 21.1 M | 25.2 M | 26.8 M | 28.7 M | 41.8 M | 43.9 M |
| LNTH | 32.8 M | 32.8 M | 27.4 M | 25.2 M | 18.3 M | 19.7 M | 18.3 M | 19.2 M | 13.9 M | 13.4 M | 24.7 M | 42.3 M | 47.9 M | 60 M | 30.7 M |
| ANIP | 139.8 K | 148.2 K | 258.9 K | 1.1 M | 3.9 M | 6.9 M | 22.3 M | 27.9 M | 33.7 M | 44.5 M | 44.6 M | 47.3 M | 57 M | 59.8 M | 62.8 M |
| IRWD | 1.7 M | 10 M | 11.3 M | 11.7 M | 12.3 M | 11.6 M | 981 K | 6.2 M | 8.1 M | 297 K | 3.6 M | 1.5 M | 1.4 M | 1.6 M | 1.5 M |
| ALKS | 600 K | 93.7 M | 73.8 M | 70.8 M | 58.2 M | 57.7 M | 61 M | 62.1 M | 72.4 M | 55.2 M | 81.9 M | 78.7 M | 77.9 M | 74.9 M | 78.7 M |
| SHPH | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 55 K | 60.8 K | 6 K | 6.8 K | 6.5 K |
| LFCR | 500 K | 5.6 M | 7.3 M | 7.1 M | 7.1 M | 9.4 M | 10.7 M | 12.4 M | 15.2 M | (4.3 M) | 8.6 M | 17.9 M | 7.1 M | 8.9 M | 6.4 M |
| ORGO | (417.4 K) | (417.4 K) | (417.4 K) | (417.4 K) | (417.4 K) | (417.4 K) | (417.4 K) | 7 M | 7 M | 9.4 M | 8.2 M | 16.7 M | 18 M | 23.4 M | 12.9 M |
Procaps Group SA and related stocks such as Evoke Pharma, Dynavax Technologies, and Amphastar P Depreciation And Amortization description
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.My Equities
My Current Equities and Potential Positions
| Procaps Group SA | PROCW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Luxembourg |
| Exchange | NASDAQ Exchange |
USD 0.0339
Additional Tools for Procaps Stock Analysis
When running Procaps Group's price analysis, check to measure Procaps Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procaps Group is operating at the current time. Most of Procaps Group's value examination focuses on studying past and present price action to predict the probability of Procaps Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procaps Group's price. Additionally, you may evaluate how the addition of Procaps Group to your portfolios can decrease your overall portfolio volatility.